Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908656 | 0.91 | KDM4E (0.50) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL13135023 | 0.91 | EPHX1 (0.61) | KDM4EMAPK1HIF1AEPHX1EPHX2 | |
| SCHEMBL26570844 | 0.86 | EPHX1 (0.68) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL14198101 | 0.85 | EPHX1 (0.68) | KDM4EMAPK1HIF1AEPHX1EPHX2 | |
| SCHEMBL22260405 | 0.85 | KDM4E (0.47) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL12913672 | 0.84 | EPHX1 (0.54) | EPHX1PAOXEPHX2PRMT1MEN1 | |
| SCHEMBL10399741 | 0.83 | EPHX1 (0.73) | KDM4EMAPK1HIF1AEPHX1EPHX2 | |
| SCHEMBL1900471 | 0.83 | KDM4E (0.82) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL12914936 | 0.82 | EPHX1 (0.58) | KDM4EMAPK1HIF1AEPHX1PAOX | |
| SCHEMBL6283812 | 0.82 | CYP2C19 (0.52) | EPHX1PAOXEPHX2TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | KDM4E 4772/4885MAPK1 3463/4885HIF1A 2224/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | KDM4E 4184/4885MAPK1 1534/4885HIF1A 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.